EANS-News: SYGNIS Pharma AG / SYGNIS strengthens its KIBRA-Project: first Patents announced for Europe and the USA
Contact: Dr. Franz-Werner Haas Senior Vice President Operations +49 (0) 6221 454 812 franz-werner.haas@sygnis.de Branche: Biotechnology ISIN: DE000A1E9B74 WKN: A1E9B7 Index: CDAX, Prime All Share Börsen: Frankfurt / regulated dealing/prime standard Berlin / free trade Hamburg / free trade Stuttgart / free trade ...